Intervertebral disc degeneration is rescued by TGFβ/BMP signaling modulation in an ex vivo filamin B mouse model

Abstract

Spondylocarpotarsal syndrome (SCT) is a rare musculoskeletal disorder characterized by short stature and vertebral, carpal, and tarsal fusions resulting from biallelic nonsense mutations in the gene encoding filamin B (FLNB). Utilizing a FLNB knockout mouse, we showed that the vertebral fusions in SCT evolved from intervertebral disc (IVD) degeneration and ossification of the annulus fibrosus (AF), eventually leading to full trabecular bone formation. This resulted from alterations in the TGFβ/BMP signaling pathway that included increased canonical TGFβ and noncanonical BMP signaling. In this study, the role of FLNB in the TGFβ/BMP pathway was elucidated using in vitro, in vivo, and ex vivo treatment methodologies. The data demonstrated that FLNB interacts with inhibitory Smads 6 and 7 (i-Smads) to regulate TGFβ/BMP signaling and that loss of FLNB produces increased TGFβ receptor activity and decreased Smad 1 ubiquitination. Through the use of small molecule inhibitors in an ex vivo spine model, TGFβ/BMP signaling was modulated to design a targeted treatment for SCT and disc degeneration. Inhibition of canonical and noncanonical TGFβ/BMP pathway activity restored Flnb ^−/− IVD morphology. These most effective improvements resulted from specific inhibition of TGFβ and p38 signaling activation. FLNB acts as a bridge for TGFβ/BMP signaling crosstalk through i-Smads and is key for the critical balance in TGFβ/BMP signaling that maintains the IVD. These findings further our understanding of IVD biology and reveal new molecular targets for disc degeneration as well as congenital vertebral fusion disorders.

References

[1] Al Kaissi A, Ghachem MB, Nassib N, Ben Chehida F, Kozlowski K. Spondylocarpotarsal synostosis syndrome (with a posterior midline unsegmented bar). Skelet. Radiol., 2005, 34: 364-366

[2] Mangaraj S, Choudhury AK, Singh M, Patro D, Baliarsinha AK. Spondylocarpotarsal synostosis syndrome. A rare case of short stature and congenital scoliosis. Clin. Cases Min. Bone Metab., 2017, 14: 258-261

[3] Mitter D, Krakow D, Farrington-Rock C, Meinecke P. Expanded clinical spectrum of spondylocarpotarsal synostosis syndrome and possible manifestation in a heterozygous father. Am. J. Med Genet A, 2008, 146A: 779-783

[4] Robertson, S. In GeneReviews(R) (eds M. P. Adam et al.) (1993).

[5] Salian S et al. Seven additional families with spondylocarpotarsal synostosis syndrome with novel biallelic deleterious variants in FLNB. Clin. Genet, 2018, 94: 159-164

[6] Yang CF et al. Filamin B loss-of-function mutation in dimerization domain causes autosomal-recessive spondylocarpotarsal synostosis syndrome with rib anomalies. Hum. Mutat., 2017, 38: 540-547

[7] Krakow D et al. Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis. Nat. Genet, 2004, 36: 405-410

[8] Breitling M, Lemire EG, Rabin M. Spondylocarpotarsal synostosis syndrome: MRI evaluation of vertebral and disk malformation. Pediatr. Radiol., 2006, 36: 866-869

[9] Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat. cell Biol., 2004, 6: 1034-1038

[10] Huelsmann S, Rintanen N, Sethi R, Brown NH, Ylanne J. Evidence for the mechanosensor function of filamin in tissue development. Sci. Rep., 2016, 6

[11] Razinia Z, Makela T, Ylanne J, Calderwood DA. Filamins in mechanosensing and signaling. Annu Rev. Biophys., 2012, 41: 227-246

[12] Stossel TP et al. Filamins as integrators of cell mechanics and signalling. Nat. Rev. Mol. Cell Biol., 2001, 2: 138-145

[13] Zhou AX, Hartwig JH, Akyurek LM. Filamins in cell signaling, transcription and organ development. Trends Cell Biol., 2010, 20: 113-123

[14] Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev., 2005, 19: 2783-2810

[15] Miyazono K, Kusanagi K, Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J. Cell. Physiol., 2001, 187: 265-276

[16] Morikawa, M., Derynck, R. & Miyazono, K. TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology. Cold Spring Harb Perspect Biol 8, a021873 (2016).

[17] Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 2003, 113: 685-700

[18] Wang RN et al. Bone Morphogenetic Protein (BMP) signaling in development and human diseases. Genes Dis., 2014, 1: 87-105

[19] Guo X, Wang XF. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res, 2009, 19: 71-88

[20] Lee KS, Hong SH, Bae SC. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene, 2002, 21: 7156-7163

[21] Lee MK et al. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J., 2007, 26: 3957-3967

[22] Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J. Biochem, 2010, 147: 35-51

[23] Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res, 2009, 19: 128-139

[24] Dituri, F., Cossu, C., Mancarella, S. & Giannelli, G. The Interactivity between TGFbeta and BMP signaling in organogenesis, fibrosis, and cancer. Cells 8, 1130 (2019).

[25] Yue J, Frey RS, Mulder KM. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene, 1999, 18: 2033-2037

[26] Hata A, Lagna G, Massague J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev., 1998, 12: 186-197

[27] Kamato D et al. Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-beta signalling. Cell. Mol. life Sci.: CMLS, 2020, 77: 243-251

[28] Miyazawa, K. & Miyazono, K. Regulation of TGF-beta family signaling by inhibitory smads. Cold Spring Harb Perspect Biol 9, a022095 (2017).

[29] Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J. Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol. cell, 2007, 25: 441-454

[30] Shen R et al. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J. Biol. Chem., 2006, 281: 3569-3576

[31] Hough C, Radu M, Dore JJ. Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PloS one, 2012, 7: e42513

[32] Kamato D, Little PJ. Smad2 linker region phosphorylation is an autonomous cell signalling pathway: Implications for multiple disease pathologies. Biomed. Pharmacother., 2020, 124: 109854

[33] Sasaki A, Masuda Y, Ohta Y, Ikeda K, Watanabe K. Filamin associates with Smads and regulates transforming growth factor-beta signaling. J. Biol. Chem., 2001, 276: 17871-17877

[34] Toomer K et al. Filamin-A as a balance between erk/smad activities during cardiac valve development. Anat. Rec. (Hoboken), 2019, 302: 117-124

[35] Zheng L, Baek HJ, Karsenty G, Justice MJ. Filamin B represses chondrocyte hypertrophy in a Runx2/Smad3-dependent manner. J. cell Biol., 2007, 178: 121-128

[36] Jarraya M et al. A longitudinal study of disc height narrowing and facet joint osteoarthritis at the thoracic and lumbar spine, evaluated by computed tomography: the Framingham Study. Spine J., 2018, 18: 2065-2073

[37] Colombier P, Clouet J, Hamel O, Lescaudron L, Guicheux J. The lumbar intervertebral disc: from embryonic development to degeneration. Jt., bone, Spine.: Rev. du Rhum., 2014, 81: 125-129

[38] Kennon JC, Awad ME, Chutkan N, DeVine J, Fulzele S. Current insights on use of growth factors as therapy for Intervertebral Disc Degeneration. Biomol. Concepts, 2018, 9: 43-52

[39] Smith LJ, Nerurkar NL, Choi KS, Harfe BD, Elliott DM. Degeneration and regeneration of the intervertebral disc: lessons from development. Dis. Model Mech., 2011, 4: 31-41

[40] Stickens D et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development, 2004, 131: 5883-5895

[41] Tolonen J et al. Growth factor expression in degenerated intervertebral disc tissue. An immunohistochemical analysis of transforming growth factor beta, fibroblast growth factor and platelet-derived growth factor. Eur. Spine J, 2006, 15: 588-596

[42] Clouet J et al. Characterization of the age-dependent intervertebral disc changes in rabbit by correlation between MRI, histology and gene expression. BMC Musculoskelet. Disord., 2011, 12

[43] Haschtmann D, Ferguson SJ, Stoyanov JV. BMP-2 and TGF-beta3 do not prevent spontaneous degeneration in rabbit disc explants but induce ossification of the annulus fibrosus. Eur. Spine J., 2012, 21: 1724-1733

[44] Huang B, Zhuang Y, Li CQ, Liu LT, Zhou Y. Regeneration of the intervertebral disc with nucleus pulposus cell-seeded collagen II/hyaluronan/chondroitin-6-sulfate tri-copolymer constructs in a rabbit disc degeneration model. Spine, 2011, 36: 2252-2259

[45] van de Laar IM et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat. Genet, 2011, 43: 121-126

[46] Caputo V et al. Novel SMAD4 mutation causing Myhre syndrome. Am. J. Med Genet A, 2014, 164A: 1835-1840

[47] Caputo V et al. A restricted spectrum of mutations in the SMAD4 tumor-suppressor gene underlies Myhre syndrome. Am. J. Hum. Genet, 2012, 90: 161-169

[48] Le Goff C et al. Mutations at a single codon in Mad homology 2 domain of SMAD4 cause Myhre syndrome. Nat. Genet, 2011, 44: 85-88

[49] Farrington-Rock C et al. Disruption of the Flnb gene in mice phenocopies the human disease spondylocarpotarsal synostosis syndrome. Hum. Mol. Genet., 2008, 17: 631-641

[50] Zieba J et al. TGFbeta and BMP dependent cell fate changes due to loss of filamin B produces disc degeneration and progressive vertebral fusions. PLoS Genet., 2016, 12: e1005936

[51] Gao S et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol. cell, 2009, 36: 457-468

[52] Sapkota G et al. Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J. Biol. Chem., 2006, 281: 40412-40419

[53] Miyazono K. Positive and negative regulation of TGF-beta signaling. J. cell Sci., 2000, 113: 1101-1109

[54] Park SH. Fine tuning and cross-talking of TGF-beta signal by inhibitory Smads. J. Biochem. Mol. Biol., 2005, 38: 9-16

[55] Lim TH et al. Rat spinal motion segment in organ culture: a cell viability study. Spine, 2006, 31: 1291-1297

[56] Yan Z et al. A Novel Organ Culture Model of Mouse Intervertebral Disc Tissues. Cells, tissues, organs, 2016, 201: 38-50

[57] Hadjipavlou AG, Tzermiadianos MN, Bogduk N, Zindrick MR. The pathophysiology of disc degeneration: a critical review. J. bone Jt. Surg. Br., 2008, 90: 1261-1270

[58] Izzi L, Attisano L. Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene, 2004, 23: 2071-2078

[59] Xie F, Zhang Z, van Dam H, Zhang L, Zhou F. Regulation of TGF-beta Superfamily Signaling by SMAD Mono-Ubiquitination. Cells, 2014, 3: 981-993

[60] Estrada KD, Retting KN, Chin AM, Lyons KM. Smad6 is essential to limit BMP signaling during cartilage development. J. Bone Miner. Res.: Off. J. Am. Soc. Bone Miner. Res., 2011, 26: 2498-2510

[61] Estrada KD et al. Smad7 regulates terminal maturation of chondrocytes in the growth plate. Developmental Biol., 2013, 382: 375-384

[62] Liu C et al. Resistin Promotes Intervertebral Disc Degeneration by Upregulation of ADAMTS-5 Through p38 MAPK Signaling Pathway. Spine, 2016, 41: 1414-1420

[63] Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci., 2008, 99: 2107-2112

[64] Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol. Biol. cell, 2003, 14: 2809-2817

[65] Hudson KD, Alimi M, Grunert P, Hartl R, Bonassar LJ. Recent advances in biological therapies for disc degeneration: tissue engineering of the annulus fibrosus, nucleus pulposus and whole intervertebral discs. Curr. Opin. Biotechnol., 2013, 24: 872-879

[66] Matta A, Erwin WM. Injectable Biologics for the Treatment of Degenerative Disc Disease. Curr. Rev. Musculoskelet. Med, 2020, 13: 680-687

[67] Vresilovic EJ, Johannessen W, Elliott DM. Disc mechanics with trans-endplate partial nucleotomy are not fully restored following cyclic compressive loading and unloaded recovery. J. Biomech. Eng., 2006, 128: 823-829

[68] Longo UG, Petrillo S, Franceschetti E, Maffulli N, Denaro V. Growth factors and anticatabolic substances for prevention and management of intervertebral disc degeneration. Stem cells Int., 2012, 2012: 897183

[69] Than KD et al. Bone morphogenetic proteins and degenerative disk disease. Neurosurgery, 2012, 70: 996-1002

[70] Nerlich AG, Bachmeier BE, Boos N. Expression of fibronectin and TGF-beta1 mRNA and protein suggest altered regulation of extracellular matrix in degenerated disc tissue. Eur. Spine J., 2005, 14: 17-26

[71] Jin H et al. TGF-beta signaling plays an essential role in the growth and maintenance of intervertebral disc tissue. FEBS Lett., 2011, 585: 1209-1215

[72] Liu C et al. Resistin promotes intervertebral disc degeneration by up-regulation of ADAMTS-5 through p38 MAPK signaling pathway. Spine, 2016, 41: 1414-1420

[73] Studer RK et al. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Spine, 2007, 32: 2827-2833

[74] Burch ML et al. TGF-beta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. Cell. Mol. life Sci.: CMLS, 2010, 67: 2077-2090

[75] Lee YJ, Kong MH, Song KY, Lee KH, Heo SH. The relation Between Sox9, TGF-beta1, and proteoglycan in human intervertebral disc cells. J. Korean Neurosurgical Soc., 2008, 43: 149-154

[76] Seto H et al. Distinct roles of Smad pathways and p38 pathways in cartilage-specific gene expression in synovial fibroblasts. J. Clin. Invest, 2004, 113: 718-726

[77] Thielen, N. G. M., van der Kraan, P. M. & van Caam, A. P. M. TGFbeta/BMP signaling pathway in cartilage homeostasis. Cells 8, 969 (2019).

[78] Hegewald AA et al. Effects of initial boost with TGF-beta 1 and grade of intervertebral disc degeneration on 3D culture of human annulus fibrosus cells. J. Orthop. Surg. Res, 2014, 9: 73

[79] Seppala J et al. Skeletal dysplasia mutations effect on human filamins’ structure and mechanosensing. Sci. Rep., 2017, 7

[80] van der Flier A et al. Different splice variants of filamin-B affect myogenesis, subcellular distribution, and determine binding to integrin [beta] subunits. J. cell Biol., 2002, 156: 361-376

[81] Krejci P et al. Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J. cell Sci., 2005, 118: 5089-5100

[82] Zimmerman LB, De Jesus-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell, 1996, 86: 599-606

[83] Inman GJ et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol., 2002, 62: 65-74

[84] DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol., 2004, 65: 744-752

[85] Favata MF et al. Identification of a novel inhibitor of mitogen-activated protein kinase. J. Biol. Chem., 1998, 273: 18623-18632

[86] Cuenda A et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett., 1995, 364: 229-233

[87] Young PR et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem., 1997, 272: 12116-12121

Funding

March of Dimes Foundation (March of Dimes)

Joseph Drown Foundation

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(F31 AR066487)

Ministerstvo Školství, Mládeže a Tělovýchovy (Ministry of Education, Youth and Sports)(LTAUSA19030)

Agency for Healthcare Research of the Czech Republic (NV18-08-00567)